Videos

Halle Moore, MD, discusses findings from a study on young breast cancer survivors who attempted pregnancy after interrupting hormone therapy.

Expert perspectives on 2 abstracts presented at ASH 2023 looking at durable continuous transfusion independence and efficacy across different risk subgroups in the IMerge phase 3 trial in MDS.

Gary J. Schiller, MD, a hematologist/oncologist, discusses the current treatment landscape for patients with lower-risk myelodysplastic syndrome [MDS].

Julie Chang, MD, discusses the reasoning behind the development of a minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma.

Brea C. Lipe, MD highlights key takeaways and patient outcomes from the PERSEUS phase three trial.

Brea C. Lipe, MD explains the trial design and patient population of PERSEUS phase three trial.

Brea C. Lipe, MD describes the unique treatment technology explored in the PERSEUS phase three trial.

Ashley Yocum, PhD, discusses the Beat AML trial of biomarker-based treatments in acute myeloid leukemia.

Jennifer A. Woyach, MD, provides an overview on some of the updated safety and efficacy data observed with pirtobrutinib in the phase 1/2 BRUIN study.

Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers discuss their key takeaways on recent updates in HER2+ breast cancer.

Daniel Stover, MD, and the Oncology Brothers review results from HER2CLIMB-02, a randomized, double-blind phase 3 trial of tucatinib and T-DM1 in patients with previously treated HER2+ metastatic breast cancer.

Medical oncologists discuss the recent update from the KATHERINE trial investigating adjuvant T-DM1 (trastuzumab emtansine) following neoadjuvant chemotherapy in patients with residual invasive HER2+ early breast cancer.

Following SABCS 2023, Daniel Stover, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the benefit of adjuvant pertuzumab and trastuzumab according to ER and HER2 expression in patients with HER2+ breast cancer.

James Zou, PhD, elaborates on some of the challenges associated with machine learning techniques and its utilization in oncology.

Clinicians discuss the importance of early detection in patients with MDS as well as providing insights into some of the unmet needs in MDS, such as a better understanding of the role of molecular alterations and its specific impact in MDS.

Hana Safah, MD explains how the risk stratification for MDS has evolved over time and provides an in-depth of the current risk stratification tools, IPSS, IPSS-R and IPSS-M.

Drs Safah and Koprivnikar review updates made to the WHO and ICC guidelines when classifying MDS as well as discussing the impact of molecular alterations when treating MDS.

Sabarish Ram Ayyappan, MD, discusses the mechanism of action of odronextamab and highlights the phase 2 ELM-2 trial which evaluated the agent in patients with relapsed/refractory diffuse large B-cell lymphoma.

Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers offer their key takeaways on recent updates in HR+/HER2- breast cancer.

Medical oncologists discuss results from the TROPION-Breast01 study investigating Dato-DXd (datopotamab deurxtecan) in patients with previously treated inoperable or metastatic HR+/HER2- breast cancer.

Hope Rugo, MD, and the Oncology Brothers review results from the INAVO120 trial studying inavolisib in combination with palbociclib and fulvestrant in PIK3CA-mutated HR+/HER2- locally advanced or metastatic breast cancer.

Experts on breast cancer review the final overall survival results from MONARCH 3 investigating abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+/HER2- advanced breast cancer.

Following SABCS 2023, Hope Rugo, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the final invasive disease-free survival analysis from the NATALEE trial in HR+/HER2- early breast cancer.

Douglas Tremblay, MD, discusses the use and potential benefits and risks of cytoreduction for patients with essential thrombocytopenia and polycythemia vera.

Francis P. Worden, MD, discusses the efficacy findings from the phase 3 COSMIC-311 study of cabozantinib in thyroid cancer.

Edward B. Garon, MD, MS, provides an overview of some of the available treatment options for patients with EGFR-mutated lung cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses the enrollment criteria and dosing for the phase 3 KEYNOTE-A18 study of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Manmeet Ahluwalia, MD, discusses the future initiatives of the Cancer Moonshot program.

Leticia Nogueira, PhD, MPH, discusses how healthcare professionals and patients can come together facing the threats of climate change on cancer care.

Manmeet Ahluwalia, MD, discusses the implications of the Cancer Moonshot program for community oncologists.